Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Research output: Contribution to journal › Article › peer-review
Colleges, School and Institutes
In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer (NSCLC). We present safety, resource use, and quality of life (QoL) results.
|Number of pages||9|
|Journal||Journal of Thoracic Oncology|
|Publication status||Published - 2012|